Agilent (A) AI Stock Analysis

• Market Cap: $34.22B
• Dividend Yield: 0.82%
• Average Volume (3M): 2.02M
• Price to Earnings (P/E): 29.7
• Beta (1Y): 1.03
• Revenue Growth: 0.56%
• EPS Growth: -4.08%
• Country: US
• Employees: 17,900
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.31
• Shares Outstanding: 284,064,730
• 10 Day Avg. Volume: 1,644,911
• 30 Day Avg. Volume: 2,019,160
• PEG Ratio: -4.10
• Price to Book (P/B): 5.37
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 23.45
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 1.33
• Enterprise Value/Gross Profit: 9.85
• Enterprise Value/Ebitda: 4.99
• 1Y Price Target: $137.23
• Price Target Upside: 13.06% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 13

• Rating: 79 Outperform
• Price Target: $129.00 ▲(6.28%Upside)

Agilent's stock score is driven by strong financial performance and positive earnings call sentiment. Short-term technical indicators provide a bullish outlook, but the valuation suggests caution due to a high P/E ratio. Continuous growth in PFAS testing and digital investments are key strengths, although challenges in the academia and government sectors require attention.

Positive Factors

Financial Performance

Agilent delivered a strong beat vs. expectations with core business strength across business lines.

Revenue Growth

Management has a clear line of sight to double-digit growth for NASD in the second half with an evolving revenue mix.

Negative Factors

Logistics Challenges

There were longer delivery times and logistic activities at ports in China that primarily impacted their instrument business since Agilent imports instruments from China.

Tariff Impacts

Tariff risks put some pressure on margins in-year, but will be fully mitigated next year.

Agilent Business Overview & Revenue Model

Company Description

Agilent Technologies, Inc. is a global leader in life sciences, diagnostics, and applied chemical markets. The company provides instruments, software, services, and consumables for the entire laboratory workflow. Agilent's core offerings serve a diverse range of industries, including pharmaceuticals, diagnostics, clinical, environmental, and food testing.

How the Company Makes Money

Agilent Technologies generates revenue primarily through the sale of scientific instruments and related products. Its revenue streams include the sale of analytical instruments, laboratory software, and consumables. The company also earns from providing installation, maintenance, and training services to its customers. Agilent maintains strategic partnerships and collaborations with various industry leaders and research institutions to enhance its product offerings and expand its market reach. The company's revenue is significantly influenced by investments in research and development, as well as by its ability to adapt to regulatory changes and technological advancements in the sectors it serves.

Agilent Financial Statement Overview

Summary

Agilent demonstrates strong financial performance with high profitability margins and efficient cost management. However, slight concerns in revenue growth and increased debt require monitoring.

Income Statement

Agilent shows a robust financial performance based on its income statement metrics. The TTM gross profit margin stands at 26.73%, indicating efficient cost management. Despite a slight decline in total revenue from previous periods, the company maintains a strong net profit margin of 17.59% for TTM, reflecting effective operational strategies. The EBIT and EBITDA margins are solid at 21.38% and 21.21%, respectively, showcasing operational efficiency and stable earnings before depreciation. However, revenue growth has slightly declined in recent reports, which could be a potential concern for future growth.

Balance Sheet

The balance sheet indicates a stable financial position with a debt-to-equity ratio of 0.57, suggesting moderate leverage. The equity ratio is healthy at 50.47%, indicating a strong asset base supported by equity. Return on equity is impressive at 19.01%, which is a testament to the company's ability to generate returns for shareholders. However, the slight increase in total debt over periods requires monitoring, as it may impact future leverage and interest obligations.

Cash Flow

Agilent's cash flow statement reflects strong cash generation capabilities. The free cash flow growth rate is positive, and the operating cash flow to net income ratio is 1.36 in the TTM, highlighting effective cash conversion from earnings. The free cash flow to net income ratio is robust at 1.20, emphasizing the company's ability to generate significant free cash flow relative to its net income. These figures suggest healthy cash management practices, though slight fluctuations in operating cash flow should be observed.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.63B	6.51B	6.83B	6.85B	6.32B	5.34B
Gross Profit	3.54B	3.54B	3.46B	3.72B	3.41B	2.84B
EBITDA	1.68B	1.87B	1.70B	1.99B	1.73B	1.35B
Net Income	1.17B	1.29B	1.24B	1.25B	1.21B	719.00M
Balance Sheet
Total Assets	12.16B	11.85B	10.76B	10.53B	10.71B	9.63B
Cash, Cash Equivalents and Short-Term Investments	1.49B	1.33B	1.59B	1.05B	1.57B	1.44B
Total Debt	3.50B	3.39B	2.73B	2.77B	2.73B	2.36B
Total Liabilities	6.02B	5.95B	4.92B	5.23B	5.32B	4.75B
Stockholders Equity	6.14B	5.90B	5.84B	5.30B	5.39B	4.87B
Cash Flow
Free Cash Flow	1.40B	1.37B	1.47B	1.02B	1.30B	802.00M
Operating Cash Flow	1.58B	1.75B	1.77B	1.31B	1.49B	921.00M
Investing Cash Flow	-1.26B	-1.26B	-310.00M	-338.00M	-749.00M	-147.00M
Financing Cash Flow	-517.00M	-752.00M	-930.00M	-1.37B	-696.00M	-717.00M

Agilent Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 121.38
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For A, the sentiment is Positive. The current price of 121.38 is above the 20-day moving average (MA) of 117.81, above the 50-day MA of 113.00, and below the 200-day MA of 127.68, indicating a neutral trend. The MACD of 1.97 indicates Negative momentum. The RSI at 63.98 is Neutral, neither overbought nor oversold. The STOCH value of 75.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for A.

Agilent Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IDXX	82 Outperform	$43.99B	50.54	59.33%	―	5.56%	4.66%
A	79 Outperform	$34.22B	29.71	18.88%	0.82%	0.56%	-4.08%
TMO	73 Outperform	$161.48B	25.10	13.73%	0.40%	0.96%	9.19%
WAT	73 Outperform	$20.94B	31.91	40.82%	―	2.57%	8.31%
DHR	72 Outperform	$145.42B	39.39	7.22%	0.63%	-9.19%	-12.75%
MTD	64 Neutral	$25.06B	30.07	-680.23%	―	1.18%	12.34%
Sector *	60 Neutral	HK$15.58B	5.65	-7.43%	4.32%	11.60%	-21.06%

Agilent Corporate Events

Agilent Expands Board, Appoints Two New Directors

On May 20, 2025, Agilent Technologies announced the expansion of its Board of Directors from 10 to 12 members, appointing Pascal Soriot and Judy Gawlik Brown as new directors. Soriot, CEO of AstraZeneca, and Brown, founder of Downtown Advisory, bring extensive experience in pharmaceuticals, biotechnology, and strategic leadership, which is expected to support Agilent’s growth initiatives. The company also amended its bylaws to streamline decision-making processes. Additionally, Heidi Kunz retired from the Board after over 20 years of service, marking a significant transition in Agilent’s leadership.

The most recent analyst rating on (A) stock is a Hold with a $130.00 price target. To see the full list of analyst forecasts on Agilent stock, see the A Stock Forecast page.